Abstract
Alfacalcidol is a widely used vitamin D compound, especially in clinical nephrology because it does not require enzymatic activation by the kidneys. For that reason it has been used for decades to treat abnormalities in bone and mineral balance that arise in chronic kidney disease. In this review an overview is provided of available experimental and clinical data that form the basis of its widespread use. Supported by studies on cell lines and animal models, clinical studies have firmly established beneficial effects of alfacalcidol on chronic-kidney disease (CKD-) related bone disease and secondary hyperparathyroidism. Its effects on muscle structure and function are not unambiguous. Neither experimental nor clinical data suggest beneficial effects of alfacalcidol on indicators of cardiovascular disease, including cardiovascular calcification, left ventricular mass function or hypertension. Suggestions of improved mortality in dialysis patients treated with alfacalcidol are based on observational cohort analyses. Integrating all available data leads the conclusion that alfacalcidol is a justifiable compound to prescribe to CKD patients with established bone disease or hyperparathyroidism. Monitoring of calcium and phosphorus levels after its initiation is required and dose adaptations should be made accordingly.
Keywords: Alfacalcidol, bone mineral density, chronic kidney disease, cardiovascular disease, CKD-MBD, secondary hyperparathyroidism, vitamin D.
Current Vascular Pharmacology
Title:Clinical Uses of 1-alpha-hydroxycholecalciferol
Volume: 12 Issue: 2
Author(s): Marc Vervloet
Affiliation:
Keywords: Alfacalcidol, bone mineral density, chronic kidney disease, cardiovascular disease, CKD-MBD, secondary hyperparathyroidism, vitamin D.
Abstract: Alfacalcidol is a widely used vitamin D compound, especially in clinical nephrology because it does not require enzymatic activation by the kidneys. For that reason it has been used for decades to treat abnormalities in bone and mineral balance that arise in chronic kidney disease. In this review an overview is provided of available experimental and clinical data that form the basis of its widespread use. Supported by studies on cell lines and animal models, clinical studies have firmly established beneficial effects of alfacalcidol on chronic-kidney disease (CKD-) related bone disease and secondary hyperparathyroidism. Its effects on muscle structure and function are not unambiguous. Neither experimental nor clinical data suggest beneficial effects of alfacalcidol on indicators of cardiovascular disease, including cardiovascular calcification, left ventricular mass function or hypertension. Suggestions of improved mortality in dialysis patients treated with alfacalcidol are based on observational cohort analyses. Integrating all available data leads the conclusion that alfacalcidol is a justifiable compound to prescribe to CKD patients with established bone disease or hyperparathyroidism. Monitoring of calcium and phosphorus levels after its initiation is required and dose adaptations should be made accordingly.
Export Options
About this article
Cite this article as:
Vervloet Marc, Clinical Uses of 1-alpha-hydroxycholecalciferol, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/15701611113119990132
DOI https://dx.doi.org/10.2174/15701611113119990132 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In vitro Vasorelaxant Effect of Artemisia herba alba Asso. in Spontaneously Hypertensive Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Co-Editor
Current Hypertension Reviews Psychological Stress and the Development of Heart Disease
Current Psychiatry Reviews Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine AMP-activated Protein Kinase as a Drug Target in Chronic Kidney Disease
Current Drug Targets Polypoidal Choroidal Vasculopathy: Recent Advances in Therapy
Current Drug Targets Systemic Sclerosis Associated Interstitial Lung Disease
Current Respiratory Medicine Reviews Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued) Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Human Fibrinogen Adsorption on Latex Particles at pH 7.4 Studied by Electrophoretic Mobility and AFM Measurements
Current Topics in Medicinal Chemistry Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Obesity and Body Composition in Man and Woman: Associated Diseases and the New Role of Gut Microbiota
Current Medicinal Chemistry Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design High Prevalence of Vitamin D Deficiency and Correlation with Cystatin-C and Other Cardiovascular and Renal Risk Biomarkers in Patients with Type 2 Diabetes Mellitus Complicated with Hypertension
Current Diabetes Reviews Aquaporin and Vascular Diseases
Current Neuropharmacology Nothing But Stress – The Interplay of Angiotensin II, Inflammation, Hypertension and Atherosclerosis: Implications for Atherosclerotic Plaque Stability
Vascular Disease Prevention (Discontinued) Drug Interactions between Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Treatments (Except Anti-Agregant Therapy)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Maternal Nutrient Restriction is not Equivalent to Maternal Biological Stress
Current Drug Targets